Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter Trial of Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

NCT07066982 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT07066982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07066982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter Trial of Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 29, 2025
Completion date
December 28, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, sarcoma metastatic, sarcoma of bone, sarcoma of bone and connective tissue, sarcoma, ewing, sarcoma, kaposi, sarcoma, synovial, sarcoma,soft tissue, sarcomas, germinoblastic